Back to Search
Start Over
Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy
- Source :
- Neurosurgical Focus. 41:E2
- Publication Year :
- 2016
- Publisher :
- Journal of Neurosurgery Publishing Group (JNSPG), 2016.
-
Abstract
- Craniopharyngiomas are rare intracranial neoplasms that pose clinical challenges due to their location adjacent to vital structures. The authors have previously shown high mutation rates of BRAF V600E in papillary craniopharyngioma and of CTNNB1 in adamantinomatous craniopharyngioma. These activating driver mutations are potential therapeutic targets, and the authors have recently reported a significant response to BRAF/MEK inhibition in a patient with multiply recurrent PCP. As these targetable mutations warrant prospective research, the authors will be conducting a national National Cancer Institute–sponsored multicenter clinical trial to investigate BRAF/MEK inhibition in the treatment of craniopharyngioma. In this new era of genomic discovery, the treatment paradigm of craniopharyngioma is likely to change.
- Subjects :
- Oncology
medicine.medical_specialty
Pathology
medicine.medical_treatment
Genomics
Pituitary neoplasm
Targeted therapy
Craniopharyngioma
03 medical and health sciences
0302 clinical medicine
Internal medicine
Biomarkers, Tumor
medicine
Humans
Pituitary Neoplasms
beta Catenin
Clinical Trials as Topic
business.industry
Disease Management
Cancer
General Medicine
medicine.disease
Clinical trial
BRAF V600E
030220 oncology & carcinogenesis
Gene Targeting
Mutation
Significant response
Surgery
Neurology (clinical)
business
030217 neurology & neurosurgery
Subjects
Details
- ISSN :
- 10920684
- Volume :
- 41
- Database :
- OpenAIRE
- Journal :
- Neurosurgical Focus
- Accession number :
- edsair.doi.dedup.....1030a9e660376200e750b90a72a08d9b